Treatment · August 1, 2026
FDA Path Clear for First Myelofibrosis Combination Therapy Targeting 2026 Approval
Karyopharm advances selinexor combination therapy toward FDA approval for myelofibrosis under expedited review....
Cancer · March 25, 2026
First Targeted Therapy Approved for Debilitating Rare Blood Disorder
The first FDA-approved treatment for a rare blood cancer marks a major milestone in addressing a previously untreatable disease....